EcoR1 Capital’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-1,249,812
Closed -$25.2M 91
2021
Q3
$25.2M Buy
+1,249,812
New +$34.5M 0.88% 22
2020
Q3
Sell
-2,721,993
Closed -$69.1M 64
2020
Q2
$69.1M Sell
2,721,993
-624,308
-19% -$13.4M 5.11% 7
2020
Q1
$61.5M Sell
3,346,301
-281,296
-8% -$5.47M 6.42% 4
2019
Q4
$79.9M Sell
3,627,597
-335,381
-8% -$6.75M 7.2% 3
2019
Q3
$56.9M Buy
3,962,978
+646,571
+19% +$9.24M 7.19% 6
2019
Q2
$52.2M Hold
3,316,407
5.28% 8
2019
Q1
$48.6M Hold
3,316,407
4.48% 9
2018
Q4
$35.5M Sell
3,316,407
-485,920
-13% -$6.39M 3.55% 11
2018
Q3
$58M Buy
3,802,327
+841,180
+28% +$12.2M 5.23% 7
2018
Q2
$36.3M Sell
2,961,147
-1,803,300
-38% -$22.7M 3.45% 9
2018
Q1
$45.5M Sell
4,764,447
-72,100
-1% -$777K 4.57% 8
2017
Q4
$43.7M Buy
4,836,547
+3,878,555
+405% +$28.5M 4.92% 7
2017
Q3
$5.51M Buy
957,992
+190,000
+25% +$691K 0.73% 24
2017
Q2
$2.44M Buy
767,992
+385,992
+101% +$1.22M 0.43% 26
2017
Q1
$1.3M Buy
+382,000
New +$1.08M 0.33% 24

Other funds holding DRNA

EcoR1 Capital's DRNA Position: Q4 2021 in Review

EcoR1 Capital sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 1,249,812 shares — an estimated $25.2M sold.

EcoR1 Capital first reported a position in DRNA in Q1 2017 and held it in 15 quarters. The position peaked at $79.9M in Q4 2019. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

  • EcoR1 Capital reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • EcoR1 Capital sold 1,249,812 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $25.2M.
  • EcoR1 Capital first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2017 and held it in 15 quarters.
  • EcoR1 Capital's Dicerna Pharmaceuticals, Inc. position peaked at $79.9M in Q4 2019.
  • 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on EcoR1 Capital's 13F filing for Q4 2021, filed 14 Feb 2022.